Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Underlying causes and survival in patients with heart failure

Article Abstract:

Identifying the cause of cardiomyopathy may allow doctors to estimate a patient's prognosis. Cardiomyopathy is a disease of the heart muscle and it has many different causes. The most common causes are hypertension and coronary artery disease. However, it can also occur during or after pregnancy, in HIV patients, and in people exposed to certain drugs. A study published in 2000 found that the prognosis of cardiomyopathy depended on the underlying cause of the disease. Women who developed the disease during pregnancy had the best prognosis compared to other groups.

Author: Givertz, Michael M.
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2000
Editorial, Prognosis, Cardiomyopathy, Myocardial diseases

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure

Article Abstract:

Patients hospitalized with worsening symptoms of congestive heart failure may benefit from the drug nesiritide. Sold under the trade name Natrecor, this drug mimics the action of a natural protein in the body brain natriuretic peptide. Researchers randomly assigned 127 patients hospitalized with worsening symptoms of congestive heart failure to take intravenous nesiritide or a placebo for up to seven days. Over 60% of those who received nesiritide experienced an improvement in symptoms compared to 14% of those receiving a placebo.

Author: Givertz, Michael M., Elkayam, Uri, Colucci, Wilson S., Horton, Darlene P., Abraham, William T., Bourge, Robert C., Johnson, Allen D., Wagoner, Lynne E., Liang, Chang-seng, Neibaur, Matthew, Haught, W. Herbert, LeJemtel, Thierry H.
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2000
Congestive heart failure agents

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Nesiritide: Not verified

Article Abstract:

Thousands of patients in the US receive nesiritide treatment once or more per week, over a period of several months, which costs around $500 per dose. However, this application of nesitiride is designated for treatment of acute, decompensated congestive heart failure by the Food and Drug Administration (FDA) in 2001 and it has safety problems and no proven clinical advantage over the existing treatments.

Author: Topol, Eric J.
Publisher: Massachusetts Medical Society
Publication Name: The New England Journal of Medicine
Subject: Health
ISSN: 0028-4793
Year: 2005
Commodity & service prices, New England States, Prices and rates, New England, Company pricing policy

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Health aspects, Drug therapy, Congestive heart failure, Natriuretic peptides
Similar abstracts:
  • Abstracts: Clinical and genetic abnormalities in patients with Friedreich's ataxia. Association between early-onset Parkinson's disease and mutations in the parkin gene
  • Abstracts: Blood money. Penny-pinching at a cost to patients with schizophrenia. Dr No
  • Abstracts: Hemoperitoneum as a result of coital injury without associated vaginal injury. It was the best of times, it was the worst of times: medicine in the 1990s
  • Abstracts: The pearl inside the twinset. Should nurses encourage parents to take up the MMR vaccine? Organ recital
  • Abstracts: Growth of telephone counselling highlights training needs. Nurse prescribing in the field of community mental health nursing
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.